Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wolstan & Goldberg Eye Associates

Neither a doctor nor a teaching hospital

Research payments

$2,017,698

354 payments

Through program year 2025, Wolstan & Goldberg Eye Associates is reported as receiving $2,017,698 in research payments, across 354 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $49,616 25
2024 Research $20,001 14
2023 Research $80,929 23
2022 Research $174,183 35
2021 Research $439,282 91
2020 Research $660,358 87
2019 Research $593,328 79

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ocular Therapeutix, Inc. $592,110 31 payments
  2. Allergan Inc. $472,604 99 payments
  3. Glaukos Corporation $289,016 82 payments
  4. Bausch Health US, LLC $241,576 40 payments
  5. Johnson & Johnson Surgical Vision, Inc. $153,100 3 payments
  6. AbbVie, Inc. $109,291 53 payments
  7. Kala Pharmaceuticals, Inc. $68,986 14 payments
  8. Bausch & Lomb Americas Inc. $53,966 7 payments
  9. Oyster Point Pharma, Inc. $18,770 17 payments
  10. New World Medical,Inc. $18,280 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Prospective Multicenter Open Label Study to Evaluate the Safety Tolerability and Efficacy of OTX TIC Implant in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension $203,956 15 payments
  2. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $192,083 19 payments
  3. A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study of the Glaukos iStent Trabecular Micro-Bypass Stent System in Conjunction with Cataract Surgery $146,023 31 payments
  4. Randomized, controlled treatment with an intracanaliuclar dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN) $137,200 4 payments
  5. Open Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension $108,452 1 payment
  6. Sur-Cat-Iol-2001 $105,600 2 payments
  7. iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $92,352 14 payments
  8. A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $80,000 5 payments
  9. A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the Envista One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction $69,354 13 payments
  10. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $68,986 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record